Evelo Biosciences Inc
NASDAQ:EVLO
EV/IC
Enterprise Value to IC
Enterprise Value to Invested Capital (EV/IC) ratio is a valuation multiple that measures the dollars in Enterprise Value for each dollar of capital invested by shareholders and lenders.
Market Cap | EV/IC | ||||
---|---|---|---|---|---|
US |
Evelo Biosciences Inc
NASDAQ:EVLO
|
18.9k USD | -6.2 | ||
US |
Abbvie Inc
NYSE:ABBV
|
287.7B USD | 3.4 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
168B USD | 2.7 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.1B USD | 7.9 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
109.5B USD | 4.4 | ||
AU |
CSL Ltd
ASX:CSL
|
134.1B AUD | 3 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
83.6B USD | 2 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
53.1B USD | 5.7 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 19.3 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
32.9B USD | 1.5 | ||
KR |
Celltrion Inc
KRX:068270
|
38.6T KRW | 2.1 |
EV/IC Forward Multiples
Forward EV/IC multiple is a version of the EV/IC ratio that uses forecasted invested capital for the EV/IC calculation. 1-Year, 2-Years, and 3-Years forwards use invested capital forecasts for 1, 2, and 3 years ahead, respectively.